31/07/2024 | Press release | Distributed by Public on 01/08/2024 21:48
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. Shield is also the first blood test for CRC screening that meets the requirements for Medicare coverage.
Read more.
Event / Digital Health / Regulatory Affairs
November 13, 2024
8:15 AM - 6:00 PM
News / Ethylene Oxide / Regulatory Affairs